These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Role of HCA₂ (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin. Hanson J; Gille A; Offermanns S Pharmacol Ther; 2012 Oct; 136(1):1-7. PubMed ID: 22743741 [TBL] [Abstract][Full Text] [Related]
4. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials. Lukasova M; Hanson J; Tunaru S; Offermanns S Trends Pharmacol Sci; 2011 Dec; 32(12):700-7. PubMed ID: 21944259 [TBL] [Abstract][Full Text] [Related]
5. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. Hanson J; Gille A; Zwykiel S; Lukasova M; Clausen BE; Ahmed K; Tunaru S; Wirth A; Offermanns S J Clin Invest; 2010 Aug; 120(8):2910-9. PubMed ID: 20664170 [TBL] [Abstract][Full Text] [Related]
6. Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Davidson MH Am J Cardiol; 2008 Apr; 101(8A):14B-19B. PubMed ID: 18375236 [TBL] [Abstract][Full Text] [Related]
7. Potential role for epidermal Langerhans cells in nicotinic acid-induced vasodilatation in the mouse. Carballo-Jane E; Ciecko T; Luell S; Woods JW; Zycband EI; Waters MG; Forrest MJ Inflamm Res; 2007 Jun; 56(6):254-61. PubMed ID: 17607550 [TBL] [Abstract][Full Text] [Related]
8. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010 [TBL] [Abstract][Full Text] [Related]
11. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Offermanns S Trends Pharmacol Sci; 2006 Jul; 27(7):384-90. PubMed ID: 16766048 [TBL] [Abstract][Full Text] [Related]
12. Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush. Meyers CD; Liu P; Kamanna VS; Kashyap ML Atherosclerosis; 2007 Jun; 192(2):253-8. PubMed ID: 16945375 [TBL] [Abstract][Full Text] [Related]
13. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721 [TBL] [Abstract][Full Text] [Related]
14. Future of GPR109A agonists in the treatment of dyslipidaemia. Wanders D; Judd RL Diabetes Obes Metab; 2011 Aug; 13(8):685-91. PubMed ID: 21418500 [TBL] [Abstract][Full Text] [Related]
15. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Oberwittler H; Baccara-Dinet M Int J Clin Pract; 2006 Jun; 60(6):707-15. PubMed ID: 16805757 [TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of niacin. Kamanna VS; Kashyap ML Am J Cardiol; 2008 Apr; 101(8A):20B-26B. PubMed ID: 18375237 [TBL] [Abstract][Full Text] [Related]
17. The effect of aspirin on niacin-induced cutaneous reactions. Whelan AM; Price SO; Fowler SF; Hainer BL J Fam Pract; 1992 Feb; 34(2):165-8. PubMed ID: 1737967 [TBL] [Abstract][Full Text] [Related]
18. The role of nicotinic acid metabolites in flushing and hepatotoxicity. Stern RH J Clin Lipidol; 2007 Jul; 1(3):191-3. PubMed ID: 21291680 [TBL] [Abstract][Full Text] [Related]
19. The mechanism and mitigation of niacin-induced flushing. Kamanna VS; Ganji SH; Kashyap ML Int J Clin Pract; 2009 Sep; 63(9):1369-77. PubMed ID: 19691622 [TBL] [Abstract][Full Text] [Related]